Literature DB >> 12390995

Dose regimen for vancomycin not needing serum peak levels?

W-H Tan1, N Brown, A W Kelsall, R J McClure.   

Abstract

AIM: To determine the safety, efficacy, and need to measure peak serum vancomycin concentrations in a neonatal population using a standard vancomycin dosage regimen.
METHOD: A total of 101 infants who were admitted to a regional neonatal intensive care unit and received vancomycin (15 mg/kg every 12 or 18 hours depending on postnatal age) were studied retrospectively. Infants who had been started on vancomycin before they were transferred to the unit were excluded. The proportion of infants was measured whose serum vancomycin concentrations were within a conservative therapeutic range of trough 5-10 mg/l, peak 20-40 mg/l, and a less conservative, but still safe, range of trough 5-12 mg/l, peak 15-60 mg/l.
RESULTS: Trough concentrations of 5-10 mg/l were achieved by 46.5% of infants, and 5-12 mg/l by 55.4%. Peak concentrations of 20-40 mg/l were found in 83.2% of infants, and 15-60 mg/l in 99.0%. Highest peak concentration was 47.2 mg/l. Some 89.4% of infants with trough concentrations of 5-10 mg/l had a peak concentration of 20-40 mg/l.
CONCLUSIONS: The vancomycin dosage regimen used in this study produces acceptable therapeutic serum vancomycin concentrations. Peak serum vancomycin concentrations do not need to be measured in neonates using this dosage regimen.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12390995      PMCID: PMC1721472          DOI: 10.1136/fn.87.3.f214

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  20 in total

1.  Rationing antibiotic use in neonatal units.

Authors:  D Isaacs
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-01       Impact factor: 5.747

2.  Vancomycin dosing in preterm infants: prospective verification of new recommendations.

Authors:  G Koren; A James
Journal:  J Pediatr       Date:  1987-05       Impact factor: 4.406

3.  Individualized pharmacokinetic profiles to compute vancomycin dosage and dosing interval in preterm infants.

Authors:  R V Jarrett; G A Marinkovich; E L Gayle; J W Bass
Journal:  Pediatr Infect Dis J       Date:  1993-02       Impact factor: 2.129

Review 4.  Serum vancomycin concentrations: reappraisal of their clinical value.

Authors:  T G Cantú; N A Yamanaka-Yuen; P S Lietman
Journal:  Clin Infect Dis       Date:  1994-04       Impact factor: 9.079

5.  Clinical pharmacology and efficacy of vancomycin in pediatric patients.

Authors:  U B Schaad; G H McCracken; J D Nelson
Journal:  J Pediatr       Date:  1980-01       Impact factor: 4.406

6.  The clinical pharmacology of vancomycin in seriously ill preterm infants.

Authors:  M D Reed; R M Kliegman; J S Weiner; M Huang; T S Yamashita; J L Blumer
Journal:  Pediatr Res       Date:  1987-09       Impact factor: 3.756

7.  Vancomycin pharmacokinetics in small, seriously ill infants.

Authors:  S H Naqvi; W J Keenan; R M Reichley; K P Fortune
Journal:  Am J Dis Child       Date:  1986-02

8.  Vancomycin pharmacokinetics and dose recommendations for preterm infants.

Authors:  A James; G Koren; J Milliken; S Soldin; C Prober
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

9.  Vancomycin pharmacokinetics in infants: relationships to indices of maturation.

Authors:  D H Schaible; M L Rocci; G A Alpert; J M Campos; M H Paul; R A Polin; S A Plotkin
Journal:  Pediatr Infect Dis       Date:  1986 May-Jun

Review 10.  Vancomycin pharmacokinetics in very low birth weight neonates.

Authors:  M B Leonard; G Koren; D K Stevenson; C G Prober
Journal:  Pediatr Infect Dis J       Date:  1989-05       Impact factor: 2.129

View more
  6 in total

1.  Pediatric pharmacokinetics of vancomycin: a canadian perspective.

Authors:  Anais Delicourt; Jean-François Bussières; Denis Lebel
Journal:  Can J Hosp Pharm       Date:  2011-03

2.  Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline.

Authors:  María-Remedios Marqués-Miñana; Anas Saadeddin; José-Esteban Peris
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

3.  Vancomycin administration: the impact of multidisciplinary interventions.

Authors:  R K Crowley; F Fitzpatrick; D Solanki; S FitzGerald; H Humphreys; E G Smyth
Journal:  J Clin Pathol       Date:  2007-02-09       Impact factor: 3.411

4.  Population Pharmacokinetic Models of Vancomycin in Paediatric Patients: A Systematic Review.

Authors:  Erin Chung; Jonathan Sen; Priya Patel; Winnie Seto
Journal:  Clin Pharmacokinet       Date:  2021-05-18       Impact factor: 6.447

5.  Immediate Treatment of Burn Wounds with High Concentrations of Topical Antibiotics in an Alginate Hydrogel Using a Platform Wound Device.

Authors:  Kristo Nuutila; Josh Grolman; Lu Yang; Michael Broomhead; Stuart Lipsitz; Andrew Onderdonk; David Mooney; Elof Eriksson
Journal:  Adv Wound Care (New Rochelle)       Date:  2019-12-18       Impact factor: 4.730

Review 6.  Target Attainment and Clinical Efficacy for Vancomycin in Neonates: Systematic Review.

Authors:  Marta Mejías-Trueba; Marta Alonso-Moreno; Laura Herrera-Hidalgo; Maria Victoria Gil-Navarro
Journal:  Antibiotics (Basel)       Date:  2021-03-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.